Washington, April 29 : Researchers at the University Hospital Basel, Basel, Switzerland have found that a widely used class of diabetes medications appears to be associated with an increased risk for fractures.
They said that diabetes drugs pioglitazone and rosiglitazone can more than double the risk of bone fractures.
"The insulin-sensitizing thiazolidinediones are a relatively new and effective class of oral antidiabetic agents that have gained wide use in clinical conditions characterized by insulin resistance," the authors write as background information in the article.
Two drugs in this category, pioglitazone and rosiglitazone, have previously shown to boost the risk for fractures among patients, since they may cause slower bone formation and faster bone loss.
In the new study, Christian Meier, M.D., of University Hospital Basel and colleagues examined 1,020 patients with diabetes who had fractures diagnosed at British general practitioners' offices between 1994 and 2005.
For each of those patients, up to four control patients with diabetes who were the same age and sex and had the same physician but did not have fractures were selected, for a total of 3,728 matched controls.
After taking into account other risk factors, researchers found that individuals who were currently taking rosiglitazone and pioglitazone had approximately double or triple the odds of hip and other non-spine fractures than those who did not take these drugs.
They also found that the odds for fracture were increased among patients who took the drugs for approximately 12 to 18 months and the risk was highest for those with two or more years of therapy.
"This analysis provides further evidence of a possible association between long-term use of thiazolidinediones and fractures, particularly of the hip and wrist, in patients with diabetes mellitus," the researchers said.
"No such effect was seen for other antidiabetic drugs in this study population. These findings, although they are consistent with recently reported data from a randomised trial, are based on relatively few thiazolidinedione-exposed patients and need to be confirmed by additional observational studies and by controlled clinical trials," they added.
The study is published in the April 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.